BPIPP is an inhibitor of GC-C (guanylyl cyclase type C) that inhibits stimulation of guanylyl cyclase and adenylyl cyclase, suppresses cGMP accumulation in a variety of cell lines (IC50=3.4-11.2 uM).

Box5 is a Wnt5a-derived N-butyloxycarbonyl hexapeptide (t-Boc-Met-Asp-Gly-Cys-Glu-Leu), acts as an Wnt5a antagonist.

Bosentan is an endothelin (ET) receptors antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.

Bosentan is a competitive and dual antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors.

Boldenone undecylenate(Equipoise) is a synthetic steroid which has a similar effect as the natural steroid testosterone; it is frequently used in veterinary medicine, though it is also used in humans.

BNS-22 is a small-molecule inhibitor of DNA topoisomerase II, inhibits kinetoplast DNA decatenation that is mediated by human TOP2α and TOP2β in vitro with IC50 of 2.8 and 0.42 uM, respectively.

BNM-III-170 TFA salt is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.

BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.

BNC-1 is a small molecule modulator of Amyloid pathology by promoting phosphorylation and activation of Elk-1, a transcriptional repressor of presenilin-1 but not presenilin-2.

BMT-145027 is a potent mGluR5 PAM with no inherent mGluR5 agonist activity.

BMT-090605 (BMT 090605, BMT090605) is a potent, selective adapter protein-2 associated kinase 1 (AAK1) inhibitor with IC50 0.6 nM.

BMT-046091 (BMT046091) is a potent and selective AAK1 inhibitor with IC50 of 2.8 nM.

BMS-986169 is a novel GluN2B negative allosteric modulator, demonstrates high binding affinity for the GluN2B allosteric site (Ki=4.0 nM) and selective inhibition of GluN2B receptor function (IC50=24 nM) in cells.

BMS-986163 is a water-soluble phosphate prodrug of BMS-986169, which is a novel GluN2B negative allosteric modulator (Ki=4.0 nM)..

BMS-986118 is a potent and selective GPR40 agonist with EC50 of 70 and 63 nM for hGPR40 and mGPR40, shows no PPARγ activity (EC50>47 uM).

BMS-986115 is an orally bioavailable, γ-secretase and pan-Notch inhibitor with potential antineoplastic activity.

BMS-984923 (BMS-984923) is a potent silent allosteric modulator (SAM) of mGluR5 with competitive antagonism of MPEPy binding with Ki of 0.6 nM, but has no detectable agonist and antagonist activity at mGluR5 signaling.

BMS-983970 (BMS983970) is a potent, orally active, pan-Notch inhibitor, demonstrates robust anti-tumor activity at tolerated doses in multiple tumor xenograft models..

BMS-961955 is an potent, allosteric inhibitor of HCV NS5B polymerase with EC50 of 7.9/4.3 nM for GT 1b/1a replicon respectively.

BMS-952048 is a positive allosteric modulator of mGluR5 with EC50 of 10 nM..

BMS-933043 is a novel highly selective, potent α7 nAChR partial agonist with binding Ki of 3.3 and 8.1 nM for rat and human α7, respectively.

BMS-919373 is a potent I(Kur)/Kv1.5 channel blocker with IC50 of 50 nM, with selectivity versus hERG, Na, Ca channels and reduced the level of brain penetration.

BMS-906024 is a highly potent, selective inhibitor of γ-secretase mediated signaling of Notch1/2/3/4 receptors with IC50 of 1.6/0.7/3.4/2.9 nM, respectively.

BMS-901715 is a potent, selective adapter protein-2 associated kinase 1 (AAK1) inhibitor..

BMS-884775 is a potent, selective P2Y1 antagonist with IC50 of 0.12 nM.

BMS-871 is a potent, orally active pan-Notch inhibitor with IC50 of 4/1/4/3 nM for Notch1/2/3/4, respectively.

BMS-869780 is a potent γ-secretase modulator (GSM) that decreases Aβ1-42 (IC50=5.1 nM) and Aβ1-40 (IC50=25.1 nM) and increases Aβ1-37 and Aβ1-38 without inhibiting overall levels of Aβ peptides or other APP processing intermediates.

BMS-823778 (BMS823778) is an orally available, potent and selective inhibitor of 11βHSD-1 with IC50 of 2.3 nM, displays >10,000-fold selectivity over 11βHSD-2.

BMS-818251 (BMS818251) is a novel potent, small-molecule inhibitor of HIV-1 entry with EC50 of 0.019 nM against e laboratory-adapted HIV-1 strain NL4-3.

BMS-817399 is a potent, selective, orally bioavailable CCR1 antagonist with binding IC50 of 1 nM, inhibits MIP-1α-induced chemotaxis with IC50 of 6 nM.